PT - JOURNAL ARTICLE AU - Chen, Gongqi AU - Chen, Shengchong AU - Huang, Chunli AU - Gu, Wei AU - Jie, Huiru AU - Zhao, Lu AU - Kong, Weiqiang AU - Gao, Jiali AU - Feng, Yuchen AU - Yi, Lingling AU - Zhen, Guohua TI - Cadherin-26 drives macrophage alternative activation via suppressing STUB1-mediated IL-4Rα ubiquitination in asthma AID - 10.1101/2024.08.01.24311333 DP - 2024 Jan 01 TA - medRxiv PG - 2024.08.01.24311333 4099 - http://medrxiv.org/content/early/2024/08/02/2024.08.01.24311333.short 4100 - http://medrxiv.org/content/early/2024/08/02/2024.08.01.24311333.full AB - Rationale IL-4 receptor (IL-4R)-mediated alternative activation of macrophage drives type 2 airway inflammation. Cadherin-26 (CDH26) upregulates epithelial type II IL-4R signaling in asthma. However, whether CDH26 contributes to type I IL-4R-mediated macrophage activation and the mechanism by which CDH26 upregulates IL-4R expression remains unknown.Objectives To investigate whether CDH26 promotes macrophage alternative activation via suppressing IL-4Rα ubiquitination-proteasomal degradation.Methods CDH26 expression in bronchoalveolar lavage cells of asthma patients was examined using quantitative PCR and immunostaining. Airway inflammation and macrophage activation were assessed in ovalbumin-sensitized and challenged macrophage-specific Cdh26-deficient mice. Mechanistic experiments included IL-4Rα degradation and ubiquitination assay, CDH26 co-immunoprecipitation and mass spectrometry analysis. Cdh26 siRNA encapsulated lipid nanoparticles were used to treat the mouse model.Measurements and Results CDH26 expression was enhanced in bronchoalveolar lavage cells from patients with eosinophilic asthma and was localized to lung macrophages. Airway eosinophilia, mucus overproduction and macrophage alternative activation were significantly suppressed in ovalbumin-challenged macrophage-specific Cdh26-deficient mice compared to control mice. Cdh26 deficiency inhibits IL-4Rα expression and STAT6 phosphorylation in macrophages in vitro. Furthermore, CDH26 knockdown enhances whereas CDH26 overexpression suppresses IL-4Rα ubiquitination and proteasomal degradation. Mechanistically, CDH26 directly interacts with STUB1 and suppresses the binding of STUB1 to IL-4Rα and subsequent ubiquitination-proteasomal degradation. Cdh26 siRNA encapsulated lipid nanoparticles markedly alleviate airway inflammation, mucus overproduction and macrophage alternative activation in the mouse model.Conclusions CDH26 interacts with STUB1 and suppresses STUB1-mediated IL-4Rα ubiquitination-proteasomal degradation, thereby amplifying IL-4R signaling in macrophages in asthma. CDH26 is a potential therapeutic target for asthma.Scientific knowledge on the subject IL-4R signaling drives macrophage alternative activation, mucous cell metaplasia, and type 2 airway inflammation in asthma, but the regulatory mechanism underlying IL-4R expression remains unclear.What this study adds to the field CDH26 expression is enhanced in lung macrophages from patients with eosinophilic asthma. Macrophage-specific Cdh26 deficiency suppresses macrophage alternative activation and airway eosinophilia in a mouse model of allergic airway inflammation. CDH26 directly interacts with STUB1 and suppresses STUB1-mediated IL-4Rα ubiquitination-proteasomal degradation, resulting in sustained activation of IL-4R signaling. Lipid nanoparticles encapsulating Cdh26 siRNA effectively alleviate airway eosinophilia and mucus overproduction in the mouse model.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by National Natural Science Foundation of China (grant 82170036), Key Research and Development Program of Hubei Province (grant 2024BCB280), Innovation and Translation Project of Tongji Hospital (grant 2023CXZH006), Natural Science Foundation of Hubei Province (2024AFB622), Research Foundation of Tongji Hospital (2023B06)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.